Literature DB >> 9182980

Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP.

U Stein1, W Walther, C M Laurencot, G L Scheffer, R J Scheper, R H Shoemaker.   

Abstract

BACKGROUND AND
PURPOSE: Cancer cells that express P-glycoprotein, multidrug resistance-associated protein (MRP), or lung resistance protein (LRP) have demonstrated resistance to a wide variety of chemotherapeutic drugs. Recently, we reported that human colon carcinoma cells that express all three proteins exhibit reduced P-glycoprotein gene expression and a loss of multidrug resistance after exposure to tumor necrosis factor-alpha, a hormone-like protein produced by cells of the immune system. In this study, we examined the effects of tumor necrosis factor-alpha on MRP and LRP gene expression in the same colon carcinoma cells.
METHODS: HCT15 and HCT116 colon carcinoma cells were incubated with tumor necrosis factor-alpha at 100 U/mL for 2, 12, 24, 48, or 72 hours; alternatively, cells transfected with an expression vector containing a human tumor necrosis factor-alpha complementary DNA were studied. The effects of tumor necrosis factor-alpha on MRP and LRP messenger RNA expression were evaluated by means of reverse transcription and the polymerase chain reaction; effects on MRP and LRP protein expression were examined by use of specific monoclonal antibodies and flow cytometry. The flow cytometry data were analyzed by use of the two-sided, nonparametric Mann-Whitney rank sum test.
RESULTS: Treatment with exogenous tumor necrosis factor-alpha reduced the level of LRP messenger RNA in both cell types in an apparently time-dependent fashion; in HCT15 cells, almost no LRP messenger RNA was detected after 48 hours of treatment. In contrast, the level of MRP messenger RNA was increased in HCT116 cells by such treatment, but the level in HCT15 cells was unchanged. Treatment with exogenous tumor necrosis factor-alpha induced changes in LRP and MRP protein expression in the two cell types that paralleled the changes found for messenger RNA. In transfected cells, the endogenous production of tumor necrosis factor-alpha reduced LRP gene expression (both messenger RNA and protein) and increased MRP gene expression (both messenger RNA and protein), regardless of cell type.
CONCLUSION: In human colon carcinoma cells, tumor necrosis factor-alpha influences MRP and LRP gene expression in opposite ways. The findings for LRP gene expression parallel our earlier findings for P-glycoprotein expression in these cells. IMPLICATION: In developing strategies for overcoming multidrug resistance in tumor cells, the possibility that an agent can suppress one or more mechanisms of drug resistance and enhance others should be considered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182980     DOI: 10.1093/jnci/89.11.807

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection.

Authors:  Johnny J Yang; David K Ann; Ram Kannan; Vincent H L Lee
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

3.  Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.

Authors:  Fatemeh Mosaffa; Fatemeh Kalalinia; Herman Lage; Jalil Tavakol Afshari; Javad Behravan
Journal:  Mol Cell Biochem       Date:  2011-12-23       Impact factor: 3.396

4.  Effect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats.

Authors:  H Ando; Y Nishio; K Ito; A Nakao; L Wang; Y L Zhao; K Kitaichi; K Takagi; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Synergistic effect of bromocriptine and tumor necrosis factor-alpha on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm.

Authors:  Lei Ding; Xiao-Ping Chen; Zhi-Wei Zhang; Jian Guan; Wan-Guang Zhang; Hai-Ping Wang; Zhi-Hui Wang; Chun-Lei Li
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

6.  Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression.

Authors:  Pedro C Lara; Marta Lloret; Bernardino Clavo; Rosa M Apolinario; Luis Alberto Henríquez-Hernández; Elisa Bordón; Fausto Fontes; Agustín Rey
Journal:  Radiat Oncol       Date:  2009-08-06       Impact factor: 3.481

7.  Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.

Authors:  Fatemeh Mosaffa; Hermann Lage; Jalil Tavakol Afshari; Javad Behravan
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

8.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

9.  Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells.

Authors:  U Stein; C Fleuter; F Siegel; J Smith; A Kopacek; D A Scudiero; K M Hite; P M Schlag; R H Shoemaker; W Walther
Journal:  Br J Cancer       Date:  2012-03-29       Impact factor: 7.640

10.  BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.

Authors:  T Yanagisawa; A Newman; H Coley; J Renshaw; C R Pinkerton; K Pritchard-Jones
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.